UNSPSC 51151546: Pilocarpine mononitrate

This classification denotes a cholinergic agonist with the molecular formula C11H16N2O2.HNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M20T465H6J, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, (3s-cis)-, mononitrate, but more generally known as pilocarpine mononitrate, which bears US NIH Compound Identifier 83930. European Medicines Agency schedules pilocarpine mononitrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03818MIG.

Most nations, for tariff purposes, schedule pilocarpine mononitrate under HS 29399990. SMILES: CC[C@H]1[C@H](COC1=O)CC2CNCN2C.[N+](=O)(O)[O-].

UNSPSC 51151546 Pilocarpine mononitrate is a Commodity code that captures pharmaceutical products, though recent state and local solicitations tagged under it reflect broader pharmacy procurement rather than pilocarpine specifically. The source shows minimal activity directly aligned with the code's nominal pharmaceutical scope; the two recent opportunities posted under this code involve naloxone procurement and direct-to-manufacturer prescription program structuring, neither of which is pilocarpine-focused. State and local governments are buying naloxone (an opioid antagonist used in overdose response) and exploring pharmacy benefit management models through this code, suggesting that either tagging precision is loose or the code is being used as a catchall for pharmaceutical procurement activity. Issuing bodies include county health departments and state health agencies, though the sample is too small to characterize a robust issuing-body mix.

Geographic activity appears limited to Florida and Texas based on recent postings. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023 and an initial two-year term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity and negotiated pricing models outside traditional pharmacy benefit manager arrangements. The code shows little recent relevant activity overall; business development teams evaluating this code should note the mismatch between its nominal scope (pilocarpine) and actual recent procurement signals (naloxone and pharmacy program structure), and clarify with issuing bodies whether tagging reflects intentional broader pharmaceutical purchasing or miscategorization.